Abbott Completes $10.7B Exact Sciences Buy, Bolsters Cancer Diagnostics
Event summary
- Abbott completed its $10.7B acquisition of Exact Sciences on March 23, 2026, making Exact Sciences a wholly owned subsidiary.
- Exact Sciences' shares ceased trading on Nasdaq on March 20, 2026.
- The deal positions Abbott as a leader in the $60B U.S. cancer screening and precision oncology diagnostics market.
- Abbott gains control of Exact Sciences' portfolio, including Cologuard, Oncotype DX, Oncodetect, and Cancerguard.
- The acquisition adds a new growth vertical to Abbott's existing high-single-digit growth expectations.
The big picture
The acquisition solidifies Abbott's position in the fast-growing cancer diagnostics market, aligning with global trends toward preventative and personalized healthcare. With Exact Sciences' portfolio, Abbott gains a competitive edge in early cancer detection and treatment optimization, addressing rising cancer incidence rates. The deal underscores the strategic importance of diagnostics in Abbott's broader healthcare portfolio, potentially driving high-single-digit growth.
What we're watching
- Integration Challenges
- How Abbott will integrate Exact Sciences' operations and pipeline to realize anticipated synergies.
- Market Penetration
- Whether Abbott can expand access to cancer screening tools globally using its operational scale.
- Pipeline Development
- The pace at which Abbott advances Exact Sciences' next-generation cancer diagnostics.
Related topics